FDA
-
-
-
-
-
-
-
BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market
-
-
-
-
-
-
-
Biorestorative Therapies, Inc. (BRTX) Confirms No Material Impact from Reciprocal Tariffs
-
-
-
-
-
-
-
BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual Meeting
-
-
-
-
-
-
-
Biorestorative Therapies (BRTX) Receives License from New York State Department of Health to act as Tissue Bank for Mesenchymal Stem Cell Processing
-
-
-
-
-
-
-
Biorestorative Therapies (BRTX) Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication
-
-
-
-
-
-
-
BioRestorative Therapies to Participate in the Roth Inaugural Healthcare Opportunities Conference
-
-
-
-
-
-
-
BioRestorative Therapies Announces Clinical Site Initiation for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

